Tilray (TLRY) Scheduled to Post Earnings on Tuesday

Tilray (NASDAQ:TLRYGet Free Report) is scheduled to post its quarterly earnings results before the market opens on Tuesday, April 9th. Analysts expect Tilray to post earnings of ($0.04) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Tilray Price Performance

TLRY stock opened at $2.43 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.63 and a quick ratio of 0.99. Tilray has a 1 year low of $1.50 and a 1 year high of $3.40. The firm has a 50-day moving average of $1.90 and a 200 day moving average of $1.98. The company has a market cap of $1.80 billion, a P/E ratio of -1.09 and a beta of 2.30.

Insiders Place Their Bets

In other news, CEO Irwin D. Simon bought 53,700 shares of the stock in a transaction dated Friday, January 12th. The stock was bought at an average price of $1.88 per share, for a total transaction of $100,956.00. Following the purchase, the chief executive officer now directly owns 2,033,058 shares in the company, valued at approximately $3,822,149.04. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Tilray news, CEO Irwin D. Simon purchased 53,700 shares of the firm’s stock in a transaction that occurred on Friday, January 12th. The stock was bought at an average cost of $1.88 per share, for a total transaction of $100,956.00. Following the purchase, the chief executive officer now directly owns 2,033,058 shares in the company, valued at $3,822,149.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Carl A. Merton acquired 20,000 shares of the company’s stock in a transaction that occurred on Friday, January 12th. The shares were acquired at an average cost of $1.87 per share, for a total transaction of $37,400.00. Following the purchase, the chief financial officer now directly owns 20,000 shares of the company’s stock, valued at $37,400. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 96,300 shares of company stock worth $183,210. Company insiders own 0.68% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TLRY. Vanguard Group Inc. grew its stake in shares of Tilray by 7.3% in the fourth quarter. Vanguard Group Inc. now owns 3,407,269 shares of the company’s stock worth $7,837,000 after acquiring an additional 231,381 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in Tilray by 35.6% in the 4th quarter. Point72 Asset Management L.P. now owns 2,362,271 shares of the company’s stock worth $5,433,000 after purchasing an additional 620,700 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Tilray during the 4th quarter valued at about $391,000. Nebula Research & Development LLC bought a new stake in Tilray during the 4th quarter valued at about $126,000. Finally, Balyasny Asset Management L.P. raised its holdings in Tilray by 154.0% in the fourth quarter. Balyasny Asset Management L.P. now owns 114,836 shares of the company’s stock worth $264,000 after buying an additional 69,628 shares during the last quarter. Institutional investors own 9.35% of the company’s stock.

About Tilray

(Get Free Report)

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Further Reading

Earnings History for Tilray (NASDAQ:TLRY)

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.